.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Johnson and Johnson
Cipla
Deloitte
Argus Health
Baxter
Mallinckrodt
Daiichi Sankyo
Chinese Patent Office

Generated: September 23, 2017

DrugPatentWatch Database Preview

Aminolevulinic acid hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for aminolevulinic acid hydrochloride and what is the scope of aminolevulinic acid hydrochloride patent protection?

Aminolevulinic acid hydrochloride
is the generic ingredient in three branded drugs marketed by Nxdc, Dusa, and Biofrontera, and is included in three NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aminolevulinic acid hydrochloride has fifty-five patent family members in twenty-two countries.

There are six drug master file entries for aminolevulinic acid hydrochloride. Two suppliers are listed for this compound.

Summary for Generic Name: aminolevulinic acid hydrochloride

Tradenames:3
Patents:6
Applicants:3
NDAs:3
Drug Master File Entries: see list6
Suppliers / Packagers: see list2
Bulk Api Vendors: see list86
Clinical Trials: see list7,038
Patent Applications: see list212
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:aminolevulinic acid hydrochloride at DailyMed

Pharmacology for Ingredient: aminolevulinic acid hydrochloride

Ingredient-typePorphyrinogens
Drug ClassPorphyrin Precursor
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
Biofrontera
AMELUZ
aminolevulinic acid hydrochloride
GEL;TOPICAL208081-001May 10, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Nxdc
GLEOLAN
aminolevulinic acid hydrochloride
FOR SOLUTION;ORAL208630-001Jun 6, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Biofrontera
AMELUZ
aminolevulinic acid hydrochloride
GEL;TOPICAL208081-001May 10, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: aminolevulinic acid hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999► Subscribe► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999► Subscribe► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999► Subscribe► Subscribe
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: aminolevulinic acid hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,223,071 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light► Subscribe
9,723,991Illuminator for photodynamic therapy► Subscribe
8,030,836Illuminator for photodynamic therapy► Subscribe
7,190,109Illuminator for photodynamic therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: aminolevulinic acid hydrochloride

Country Document Number Estimated Expiration
Slovenia1027093► Subscribe
Spain2323073► Subscribe
Portugal1027093► Subscribe
Australia1278399► Subscribe
Germany59908665► Subscribe
South Africa200104726► Subscribe
Australia1271000► Subscribe
Denmark1566200► Subscribe
Germany69940488► Subscribe
Norway319662► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Cerilliant
McKesson
Novartis
Healthtrust
Citi
Argus Health
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot